Market Newsdesk

• Ended 2020 with $1.1 Million in Cash and Cash Equivalents
• Introduced Upcoming TerraVis^™ Product Line
• Announced Tier-One OEM Supply Agreement with Major EV Manufacturer

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTC: WKSP) (or the “Company”) a developer and manufacturer of high quality, modular, and attractively priced tonneau covers and solar-powered systems for light-duty trucks, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Steven Rossi, Chief Executive Officer of Worksport said, “Worksport today is a significantly stronger and more diversified company than it was a year ago. Like most companies, the Covid-19 pandemic significantly impacted operations but our capital structure, which includes no long-term debt, allowed us to use that time to lay the groundwork for what we believe will be significant revenue growth in the future. We now have a full line of innovative tonneau covers that have been meticulously scrutinized as we retooled for greater manufacturing capacity in preparation for the 2021 production year. Most importantly, in late August, we introduced TerraVis™, revolutionary development in the emerging EV market that we believe is a transformative step in our evolution, and to that end we announced an agreement with Hercules Electric Mobility Inc. to become a Tier-One OEM supplier for their highly anticipated Alpha Electric Pickup, with over US $27 million in early customer reservations. Finally, and as a testament to the enthusiasm investors have for Worksport, late in 2020 we initiated a Reg-A offering which by December 31, 2020 had raised more than $1 million, and by the time we closed the offering in February 2021, had raised more than $4 million. This capital will allow us to invest in manufacturing capabilities, building inventory, and boosting our marketing and branding efforts. With an anticipated surge in consumer spending many say will follow the end of the pandemic, and the emerging market for electric vehicles and accessories, Worksport is well-positioned to benefit from these developing trends.”

Subsequent Events

• In February 2021, Worksport closed its oversubscribed Reg-A offering, raising more than $4 million
• To date, Worksport received an additional $2.9 million from the exercise of warrants associated with its Reg-A offering
• Worksport raised $3 million from non-brokered Private Placement

Full Year 2020 Financial Results

For the year ended December 31, 2020, total revenues were $346,144, compared to $1,926,405 for the year ended December 31, 2019.

Net loss for the year ended December 31, 2020 was $1,187,620 compared to a net loss of $359,034 for the prior year period.

Total cost of sales for the year ended December 31, 2020 decreased by 82% from $1,687,857 to $298,996 for the prior year period.

General and administrative expenses were $201,929 in 2020 compared to $238,841 for the prior year period.

To stay up-to-date on all the latest Worksport news… investors, supporters, and shareholders are encouraged to follow the company’s social media accounts on Twitter, Facebook, LinkedIn, and Instagram, as well as sign up for the company’s newsletters at www.worksport.com and www.goterravis.com.

About Worksport Ltd.

Worksport Ltd. (currently OTCQB: WKSP) develops and manufactures high quality, modular, and attractively priced tonneau covers and solar-powered systems for light-duty trucks such as the Sierra, Silverado, Canyon, RAM, Ford F-Series, et al. and consumer-oriented adventures & purposes, where portable energy is a necessity. Available soon to pre-order, the modular, redefining Worksport TerraVis^™ tonneau cover system is being mindfully designed for the jobsite contractor and off-road, light-duty trucker, for work and play, to sustainably supply extra energy for those additional miles. Expected to launch by end of year 2021, its allied TerraVis COR^™ mobile energy storage system (ESS), will be another redefining product targeted for vacationers, second-home owners, and campers. Plans are also being constructed to expand with grid micro-charging stations to provide convenience and efficiency in recharging to smaller form-factor EVs. For more information, please visit www.worksport.com and www.goterravis.com.

Connect with Worksport:

LinkedIn

Facebook

Twitter

Instagram

For further information please contact:

Mr. Steven Rossi
CEO & Director
Worksport, Ltd
T: 1-888-554-8789
E: [email protected]

Forward-Looking Statements

This document may contain forward-looking statements, relating to Worksport, Ltd. operations or to the environment in which it operates, which are based on Company estimates, forecasts, and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, and/or are beyond Worksport, Ltd.’s control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. Worksport, Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. No Stock Exchange or Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) — Mizuho Americas today announced the hiring of John Baumgartner, CFA, as Managing Director and Senior Consumer Equity Research Analyst covering the US food industry, including plant-based alternatives and healthy lifestyle companies. Baumgartner will be based in NY and is the latest addition to Mizuho’s global consumer franchise which includes Michael Dick, Managing Director, US Consumer/Retail Trading & Specialist Sales also based in NY, and Hiroshi Saji, Director, Equity Research and Toshio Takahashi, Director, Equity Research in Japan. Hiroshi Saji (ranked third in the 2021 Nikkei Veritas survey for Food, Beverages & Tobacco) covers Japanese food & beverage, retail and personal care, and Toshio Takahashi (ranked second in the 2021 Nikkei Veritas survey for Retail) covers Japanese retail. Baumgartner will report to Managing Director and Head of US Equity Research, Susan Gilbertson.

“Over a year into the coronavirus pandemic, consumers are more focused on healthier eating habits. As a result, plant-based eating has become more mainstream and companies are working on innovative ways to bring these types of products to market as soon as possible,” said Gilbertson. “Against this backdrop, we are excited to add John’s deep consumer industry expertise to expand our research coverage.”

Baumgartner joins Mizuho from Wells Fargo Securities where he served as Director of Equity Research for Food and Agribusiness. Prior to that, he was the Senior Equity Research Analyst for U.S. food at Telsey Advisory Group, and an Agriculture Strategist for Global Commodities Research at Goldman Sachs. Baumgartner holds a Bachelor of Science degree in Finance, with Highest Honors, from Rutgers University.

Baumgartner is joined by Misa Batcheller, also from Wells Fargo Securities, where she served as an Equity Research Associate for consumer packaged food (CPG) and an Economic Research Analyst prior to that. Batcheller holds a Bachelor of Arts in Economics, from Wake Forest University.

About Mizuho Americas

Mizuho Americas is a leading provider of a broad range of financial services, including corporate and investment banking, lending, custody, treasury services, research and capital markets solutions. With professionals across the U.S., Canada, and Latin and South America, Mizuho Americas supports corporate clients, institutional investors, and public sector organizations by connecting local markets to a vast global network. To learn more about Mizuho Americas’ business, values, and ethical commitments, and the entities it comprises, visit to www.mizuhogroup.com/americas.​

Mizuho Americas is an integral part of the Japan-based Mizuho Financial Group, Inc. (NYSE: MFG). Mizuho Financial Group is one of the largest financial institutions in the world, offering comprehensive financial and strategic services through its subsidiaries. The group has approximately 900 offices and 60,000 employees worldwide in nearly 40 countries throughout the Americas, EMEA, and Asia. As of December 31, 2020, its total assets were $2.1 trillion. Learn more about Mizuho Financial Group at www.mizuhogroup.com​.​​​

For inquiries, please contact:
Jim Gorman
Director, Media Relations, Mizuho Americas
+1-212-282-3867
[email protected]

Laura London
Vice President, Media Relations, Mizuho Americas
+1- 212-282-4446
[email protected]

GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming virtual investor conferences in May 2021.

Details for Upcoming Conferences:

Event:	7th Annual Truist Securities 2021 Life Sciences Summit
Date and Time:	May 4-5, 2021
Participation:	Management will participate in a virtual fireside chat that is scheduled for Tuesday, May 4th at 11:20 AM ET, as well as 1-on-1 meetings virtually
Event:	Oppenheimer MedTech Summit
Date and Time:	May 26, 2021
Participation:	Management will be available for 1-on-1 meetings virtually

Please contact your representative at either Truist Securities or Oppenheimer to schedule a virtual one-on-one meeting with Beyond Air during the respective conference.

About Beyond Air, Inc.

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit^®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. LungFit^® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit^® for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

Forward Looking Statements

This press release contains “forward-looking statements” concerning inhaled nitric-oxide and the Company’s LungFit™ product, including statements with regard to potential regulatory developments, the potential impact on patients and anticipated benefits associated with its use. Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “anticipates,” “expects,” “intends,” “impacts,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history and other risks identified and described in more detail in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:

Steven Lisi, Chief Executive Officer
Beyond Air, Inc.
[email protected]

Maria Yonkoski, Head of Investor Relations
Beyond Air, Inc.
[email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
(212) 915-2577

SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyr’s monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.

Under the terms of the agreement, Lonza will utilize its Ibex^® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810. The agreement will cover the early stages from gene to Investigational New Drug (IND) and will provide both drug substance (DS) and drug product (DP) to support toxicological studies in animals and early clinical development in humans.

The scope will include process support, including cell line development, process development, and supply chain simplification, to DS and DP manufacturing at Lonza’s Visp and Stein (CH) sites.

“As we prepare to advance ATYR2810 to clinical stage development, we are pleased to work with Lonza, a partner with extensive and proven capability in antibody manufacturing, for the production of our first anti-NRP2 antibody,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Having recently initiated IND-enabling activities for ATYR2810 following some compelling preclinical data in triple-negative breast cancer, strengthened by additional data in lung cancer, this agreement with Lonza reflects our commitment to this program and will support our efforts to eventually advance ATYR2810 to in-patient trials in cancer, including certain aggressive tumors where NRP2 is implicated.”

“We look forward to supporting aTyr as they advance their novel therapeutic antibody from preclinical stages into the clinic. This collaboration signifies our commitment and flexibility in accommodating the specific and unique needs of small biotech companies,” said Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza.

Abo
ut ATYR2810

aTyr is developing ATYR2810 as a potential therapeutic for certain aggressive tumors where Neuropilin-2 (NRP2) is implicated. ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF. ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr’s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways. NRP2 is a cell surface receptor that is highly expressed in certain tumors, in the lymphatic system and on key immune cells implicated in cancer progression. Increased NRP2 expression is associated with worse outcomes in many cancers. Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors. ATYR2810 is currently undergoing IND-enabling studies.

Abo
ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Abo
ut Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com.

Follow @Lonza on LinkedIn

Follow @LonzaGroup on Twitter

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of NRP2 antibodies, including ATYR2810; timelines and plans with respect to certain development activities; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information and Disclaimer for Lonza

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

aTyr Pharma Contact Details

Ashlee Dunston

Director, Investor Relations and Corporate Communications
aTyr Pharma
[email protected]

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
[email protected]

Dr. Martina Ribar Hestericová

Trade Media Lead
Lonza Group Ltd
Tel +41 61 316 8982
[email protected]

Dirk Oehlers

Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
[email protected]

VANCOUVER, British Columbia, April 14, 2021 (GLOBE NEWSWIRE) — Independence Gold Corp. (TSX.V: IGO) (“Independence” or “the Company”) is pleased to provide an update on the 3Ts Project (the “Property”), including assay results from the first drill hole of a 4,500 metre (“m”) winter diamond drilling program, a re-analysis of drill hole 3T-20-06 (drilled in 2020) to identify other potential elements of interest, and plans for a detailed geophysical survey to be carried out over the Property.

The 2021 winter drill program was designed to test significant gaps within the historical drilling of the Tommy and Ted-Mint vein systems, both along strike and at depth, as well as previously untested targets. Drill hole 3T-21-01 was designed to test the Ted-Mint Offset Vein below the microdiorite sill, and highlights include:

Drill Hole	From (m)	To (m)	Drill Intercept (m)	Au (g/t)	Ag (g/t)
3T-21-01	293.35	307.00	13.65	5.07	258.10
Including	293.35	299.2	5.85	8.60	577.62

Upon further review of previous drill results, the Company re-analyzed data from the 2020 drill program in order to identify other elements of economic interest, notably copper (“Cu”), lead (“Pb”), molybdenum (“Mo”) and zinc (“Zn”). Drill hole 3T-20-06 was selected as it was one of the deepest holes drilled to date and reached a depth of approximately 150 m below the microdiorite sill. Highlights from the analysis include:

Drill Hole	From (m)	To (m)	Drill Intercept (m)	Cu* (%)	Mo (ppm)	Pb (ppm)	Zn* (%)
3T-20-06	401	409	8	0.07	56.75	818.75	0.44
Including	404	406	2	0.15	140.67	583.33	1.01
Including	404	407	3	0.21	209.00	852.50	0.92
Including	403	406	3	0.16	145.00	2,095.33	0.69
*Results for copper and zinc were reported in parts per million by the assaying lab and have been converted to a percentage using 1% = 10,000 ppm

Several other deep drillholes from the 2020 drill program, as well as earlier programs, will also be selected to identify and re-analyzed for these elements of interest. Based on alteration studies, geochemistry and geological work the Company has identified the potential for a porphyritic system underlying the 3Ts Property.

The Company has entered into a contract with Dias Geophysical to carry out a program of deep 3D IP and resistivity surveying, and a magnetic tellurics (“MT”) survey with the DIAS32 system, which will commence during the third week of April. The 3D IP survey will be completed on surface and in boreholes across a survey area of approximately 4 km by 2 km, with a goal of imaging the geology beneath the microdiorite sill. A portion of the 3D IP survey will be completed at a higher spatial resolution in order to image potential epithermal vein systems in the near surface. The MT survey will be completed over the same survey area with the goal of extending the depth search to over 1.5 km to help in imaging for potential porphyry sources and major structural features.

The 3Ts Project is located approximately 185 kilometres (“km”) southwest of Prince George, British Columbia and situated 20 km southwest of Artemis Gold’s Blackwater Gold Deposit. Please refer to the website for maps showing the vein locations.

About Independence


Independence Gold Corp. (TSX.V:IGO) is a mineral exploration company listed on the TSX Venture Exchange. The Company’s holdings range from early-stage grassroots exploration to advanced-stage resource expansion in British Columbia and Yukon. For additional information, visit the Company’s website www.ingold.ca.

Andy Randell, P.Geo., the Company’s Qualified Person as defined by National Instrument 43-101, has reviewed the technical information in this news release.

ON BEHALF OF THE BOARD OF INDEPENDENCE GOLD CORP.

“Randy Turner”

Randy Turner, President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to Independence within the meaning of applicable securities laws, including statements with respect to the Company’s planned drilling and exploration activities. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in Independence’s public filings under Independence Gold Corp.’s SEDAR profile at
www.sedar.com
.  Although Independence has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Independence disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Contact:
Telephone: 604-687-3959
Facsimile: 604-687-1448
E-Mail: [email protected] 

Investors with losses are encouraged to contact the firm before April 26, 2021; click


here


to submit trade information

LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Infinity Q Capital Management LLC (NASDAQ: IQDNX) investors that acquired shares between December 21, 2018 and February 22, 2021. Investors have until April 26, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

The investigation focuses on whether Infinity Q issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Infinity Q recently announced that its Chief Investment Officer had made changes to the methodology used for valuing assets held by the fund and that “it was unable to conclude that these adjustments were reasonable, and, further, that [Infinity Q] was unable to verify that the values it had previously determined for the [assets] were reflective of fair value.” Infinity Q sought to suspend redemptions, which the Wall Street Journal notes “suggests severe problems at the firm.”

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

PRESS RELEASE

April 14, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021.

SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, K_Ca3.1. This ion channel is found in immune cells and fibroblasts, and it controls the proliferation, migration and release of cytokines and collagen. Previous studies have indicated that K_Ca3.1 inhibition may reduce inflammation and fibrosis in various diseases. Saniona is currently evaluating SAN903 in preclinical models of multiple rare inflammatory and fibrotic disorders and expects to initiate Phase 1 clinical trials in the first half of 2022.

At the ASPET conference, Saniona will present a poster titled, “Comparison of K_Ca3.1 Inhibitor, SAN903, with Nintedanib and Pirfenidone in an Idiopathic Pulmonary Fibrosis Model.” The abstract (L5029) is available on the meeting website and the poster is also available online to registered attendees from April 13 to May 31, 2021. Saniona also plans to share its SAN903 preclinical data in additional scientific and investor forums in the future.

“SAN903 was discovered in Saniona’s labs and provides an excellent example of the potential of our proprietary ion channel drug discovery engine to yield new treatments for rare diseases,” said Jørgen Drejer, Chief Scientific Officer of Saniona. “We have previously demonstrated in multiple preclinical models the ability of SAN903 to selectively target and completely inhibit K_Ca3.1, and the new data we are presenting at ASPET further strengthen our confidence in this molecule as a potential treatment for rare inflammatory and fibrotic disorders.”

For more information, please contact

Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 14 April 2021.

About Saniona

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical studies. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment

• ASPET curtain raiser press release_04.14.21

FOSTER CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) — GridGain^® Systems, provider of enterprise-grade in-memory computing solutions based on Apache^® Ignite^®, today offered a preview of speakers for the first Ignite Summit, including representatives from IBM, BNP Paribas CIB, and GridGain. The free virtual Ignite Summit will take place May 25, 2021. The Call for Papers closes on April 30, 2021.

Organized by GridGain, the 2021 Ignite Summit is intended for developers and architects and members of the Apache Ignite community working with Apache Ignite, distributed databases or other in-memory computing solutions to solve application speed and scale challenges. Registration for the virtual event is open to anyone, anywhere in the world.

“In-Memory Data Grids such as Apache Ignite have become an essential infrastructure technology for powering modern applications that meet the performance and scalability demands of today’s businesses,” said Shahir Daya, IBM CTO and Distinguished Engineer and a featured speaker at the Summit. “The Ignite Summit is bringing together some of the world’s most experienced Ignite developers and users to share their knowledge and experiences, and I’m incredibly pleased to be participating. I hope that everyone looking to modernize their core applications will attend.”

Sneak Peek Speaking Sessions

How IBM Leverages Event-Driven Architecture with Apache Ignite for Core Application Modernization – Shahir Daya, IBM Distinguished Engineer and CTO – To offer clients next-generation experiences and compete with new entrants, organizations must modernize their core applications and take advantage of modern architectural patterns such as microservices and event-driven architectures. Modernizing old and fragile applications can be very challenging, time-consuming, and risky. You must establish a modern target architecture and a coexistence architecture, and you need to simplify and standardize the integration. This session will describe an event-driven Book of Reference pattern we call the “Digital Core” that enables incremental modernization or complete replacement of a core system of record. The pattern handles both streaming and batch data, leverages an industry-aligned data model, and has a speed layer based on Apache Ignite, among other capabilities.

Apache Ignite as a Hybrid Transactional/Analytical Processing (HTAP) Solution at a Large Investment Bank – Emmanuel Wiesenfeld, Lead Developer at BNP Paribas CIB – BNP Paribas’s Apache Ignite cluster is being used globally across all divisions of our corporate investment bank. Ignite uses 600 CPU cores and 9 TBs of RAM to handle a steadily increasing number of users, multiple complex HTAP operations, and events that come from various data sources. This session will describe our experience in designing, building, and optimizing an HTAP solution that is powered by Ignite and enables BNP Paribas to make key business decisions in real time. Topics include reasons for choosing Ignite; best practices and tradeoffs when designing an HTAP solution; tips and tricks for using Ignite compute, SQL, key-value, and streaming APIs; and optimization tactics for Ignite clusters with native persistence.

Apache Ignite Storage Engine Architecture: Tradeoffs and a Retrospective – Alexey Goncharuk, Chief Architect at GridGain and Apache Ignite PMC Member – The Apache Ignite native persistence storage engine follows a classic database approach based on ARIES architecture, which Ignite developers adapted to increase development velocity and facilitate memory-only storage. This session is intended for architects and engineers who want to learn more about ARIES and Apache Ignite architectures, and will provide an overview of the storage engine and the tradeoffs and reasoning that Ignite developers made during development. Attendees will also learn about the challenges faced during the implementation of the chosen approach in Java and how the Ignite community overcame them.

Ignite Summit Committee

• 
  Dmitry Pavlov
  , Apache Ignite PMC Chair, Sberbank Technology Chief Technology Expert
• 
  Valentin Kulichenko
  , Apache Ignite PMC, GridGain Director of Product Management
• 
  Saikat Maitra
  , Apache Ignite PMC, Target Corporation Principal Engineer
• 
  Maxim Muzafarov
  , Apache Ignite PMC, Sbertech Java Team Lead
• 
  Denis Magda
  , Apache Ignite PMC, GridGain VP of Developer Relations

Event Summary

What: Virtual Ignite Summit
When: May 25, 2021
Where: Online
Register: Ignite Summit website

Ignite Summit is organized by GridGain Systems, an Apache Software Foundation (ASF) sponsor. The ASF is a community sponsor of the Ignite Summit.

About Apache Ignite

Apache Ignite is an open source in-memory computing platform that can be used as a distributed cache, an in-memory data grid, or as a standalone distributed in-memory database. Ignite delivers unprecedented speed, massive scalability, and real-time data access for both legacy and greenfield applications. Apache Ignite is used by American Airlines, Apple, Banco do Brasil, Bloomberg, Dreamworks, Dutch Railways, Homeaway, IBM, ING Bank, Microsoft, Netflix, PayPal, Teradata, and UPS, among many others. For more information, visit ignite.apache.org.

About GridGain Systems

GridGain developed and donated the original Ignite code to The Apache Software Foundation (ASF) in 2014. GridGain is a Bronze Sponsor of the ASF, and members of the GridGain team are active contributors to the Apache Ignite project. For more information, visit gridgain.com.

CONTACT:

Brigit Valencia
For GridGain Systems
[email protected]
(360) 597-4516

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) — Verizon Media today announced the launch of its Next-Gen Solutions suite, a first-to-market offering for advertisers and publishers independent of cookies or mobile app IDs for audience creation, buying or measurement. Built for the identity-less era, this suite of solutions delivers relevant ad experiences while strengthening consumer trust.

As the ad ecosystem moves away from browser cookies and app advertising IDs, and legislation and privacy preferences shift, advertisers and publishers need solutions that help reach consumers in relevant and meaningful ways in the absence of IDs.

Verizon Media’s Next-Gen Solutions use content and other real-time data signals like weather, and location and device types to power machine-learning algorithms that allow advertisers to connect with their most relevant audiences without the need for cookies, mobile app IDs, browser storage or creating user-level profiles.

The new suite is an extension of Verizon Media’s identity-enhanced offerings, which also include ConnectID, a unified identity solution built on top of Verizon Media’s diverse and consent-based identity graph. Advertisers and publishers now have solutions for when an ID is present with ConnectID, or when they’re facing the challenge to reach and connect in meaningful ways with identity-less opportunities. With a full-stack, unified ad platform, Verizon Media is uniquely positioned to help advertisers and publishers navigate the identity-less future simply and effectively.

“The future of Identity lies in striking the right balance of providing a meaningful consumer experience and delivering growth for advertisers and publishers, while also preserving consumer trust,” said Iván Markman, Chief Business Officer, Verizon Media. “For advertisers who want to future-proof their businesses in an identity-constrained future, innovative solutions for non-addressable inventory are a necessity, not a choice. This is why we’re launching Next-Gen Solutions, helping advertisers achieve targeted scale, delivering relevant consumer experiences, and enabling better publisher monetization in the identity-less world.”

The Next-Gen Solutions suite of audience creation, buying and measurement tools include:

Next-Gen Audiences — Audiences created from machine-learning models built on Verizon Media’s extensive first-party data signals. Enriched by contextual and real-time signals, Next-Gen Audiences leverage existing demo, interest, income, look-alike and predictive audience signals in an aggregated, privacy-centric manner. This offering provides ad campaign accuracy and performance for brands, agencies and publishers for identity-less impressions.

Next-Gen Buying — Leveraging Next-Gen Audiences, Next-Gen Buying is natively integrated into the Verizon Media DSP for seamless buying and delivery. Machine learning-based frequency capping limits over-exposures and maintains healthy end-user marketing experiences for identity-less impressions. With Nex-Gen Buying built-in, Verizon Media DSP optimizes advertiser campaigns by intelligently bidding between addressable and identity-less supply.

Next-Gen Measurement — As cookies and mobile app IDs disappear, conversion blindspots and inaccuracies will explode, severely limiting the ability to connect touchpoints for measurement. Additionally, siloed or clean-room measurement solutions may hamper understanding customer journeys or true ROAS. With Next-Gen Measurement, advertisers maintain omnichannel insights and measurement. To achieve this, Next-Gen Measurement combines Verizon Media’s measurement methodology, based on first-party aggregated data, with third-party solutions provided by browsers and operating systems, to provide a comprehensive, reliable and privacy-preserving foundation for measurement.

Advertisers will be able to access Next-Gen Audiences and Next-Gen Buying in Q2. Next-Gen Measurement will be available by Q4 2021.

“As the industry continues to shift, the divide is now sharper between those that have first-party data and those that do not, creating new challenges and opportunities to sustain and accelerate business growth” said Markman. “With today’s news, we are extending our ability to better serve our customers, offering solutions for both identity-led and identity-less opportunities.”

About Verizon Media

Verizon Media, a division of Verizon Communications, Inc., houses a trusted media ecosystem of premium brands like Yahoo, AOL, TechCrunch and Engadget to help people stay informed and entertained, communicate and transact, while creating new ways for advertisers and media partners to connect. From XR experiences to advertising and content technology, Verizon Media is an incubator of innovation and is revolutionizing the next generation of content creation in a 5G world.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $128.3 billion in 2020. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/news. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:

Gareth Jordan
[email protected]
+44 7980 942 887

SOUTH COAST METRO, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Golden State, an investment advisor registered with the SEC, is pleased to announce its expansion into Arizona with the addition of David M. Eldridge, CRPC℠ of Eldridge Capital Group to the team. Located in Phoenix, David is passionate about helping clients navigate important life decisions and achieve their financial goals. He brings to Golden State a diverse background in the financial services industry spanning 11 years. Along with being a valued advisor to his clients, his prior roles included business development and technology solutions.

“It is this kind of breadth of experience that David brings to Golden State that allows us to continue to build a definitive network of financial advisors that provide an invaluable service to their communities.” says Daniel R. Catone, Founder and CEO of Golden State.

In his free time, David spends time with his wife and four children. He and his family enjoy hiking in the great outdoors. He is active in his church community and also enjoys taking his motorcycle out on the road. Learn more about David at eldridgecapitalgroup.com.

About Golden State

The Golden State family of companies, comprised of Golden State Wealth Management, Golden State Equity Partners and Golden State Asset Management, are investment advisers registered with the SEC dedicated to financial professionals and their clients. The firm’s initial company was founded in 2013 by a group of executives who collectively contribute over 50 years of industry experience and has partnered with advisors serving over $2 billion in brokerage and advisory assets¹. Golden State’s infrastructure provides an extensive support network through succession planning, compliance oversight, dedicated transition support, and a Turnkey Asset Management Program. The Golden State family of companies maintain business alignments with LPL Financial, the nation’s largest independent broker/dealer², Raymond James, TD Ameritrade Institutional and Charles Schwab, some of the nation’s largest independent custodians, who provide comprehensive tools and research necessary in today’s complex markets.

Recognized as one of Orange County’s largest RIAs³, Golden State’s flagship office is located in South Coast Metro, California. With a goal to continue expanding offices across the country, Golden State is committed to creating an atmosphere that benefits both advisors and their investors. For more information about Golden State, visit www.teamgoldenstate.com.

¹As of December 2020.
²As reported in Financial Planning magazine, June 1996-2020, based on total revenue.
³As reported in Orange County Business Journal, June 1, 2020, based on assets under management.

Investment advice offered through Golden State Equity Partners, an investment adviser registered with the SEC.

Media Inquiries:
Jennifer Nahas
[email protected]
949-433-6860